Cargando…

Active Targeted Nanoemulsions for Repurposing of Tegaserod in Alzheimer’s Disease Treatment

Background and Purpose: The activation of 5-HT(4) receptors with agonists has emerged as a valuable therapeutic strategy to treat Alzheimer’s disease (AD) by enhancing the nonamyloidogenic pathway. Here, the potential therapeutic effects of tegaserod, an effective agent for irritable bowel syndrome,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Séguy, Line, Guyon, Léna, Maurel, Manon, Verdié, Pascal, Davis, Audrey, Corvaisier, Sophie, Lisowski, Vincent, Dallemagne, Patrick, Groo, Anne-Claire, Malzert-Fréon, Aurélie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8540544/ https://www.ncbi.nlm.nih.gov/pubmed/34683919 http://dx.doi.org/10.3390/pharmaceutics13101626

Ejemplares similares

Design of Non-Haemolytic Nanoemulsions for Intravenous Administration of Hydrophobic APIs
por: Séguy, Line, et al.
Publicado: (2020)

Pharmacotechnical Development of a Nasal Drug Delivery Composite Nanosystem Intended for Alzheimer’s Disease Treatment
por: Adnet, Thomas, et al.
Publicado: (2020)

Repurposing the serotonin agonist Tegaserod as an anticancer agent in melanoma: molecular mechanisms and clinical implications
por: Liu, Wei, et al.
Publicado: (2020)

Tegaserod for the Treatment of Irritable Bowel Syndrome
por: Madia, Valentina Noemi, et al.
Publicado: (2020)

Comments on Tegaserod Trial on Irritable Bowel Syndrome
por: Jung, Hye-Kyung
Publicado: (2010)

Estimation of Tegaserod Maleate by Differential Pulse Polarography
por: Rajput, S. J., et al.
Publicado: (2009)

Exploratory Study of Tegaserod for Dyspepsia in Women Receiving PPIs for Heartburn
por: Vakil, Nimish, et al.
Publicado: (2008)

Sensitization of ovarian carcinoma cells to Bcl-x(L)-targeting strategies through indirect modulation of Mcl-1 activity by MR22388, a molecule of the tripentone family
por: Tomasina, Julie, et al.
Publicado: (2013)

Tegaserod in the treatment of irritable bowel syndrome (IBS) with constipation as the prime symptom
por: Layer, Peter, et al.
Publicado: (2007)

Tegaserod Maleate Inhibits Breast Cancer Progression and Enhances the Sensitivity of Immunotherapy
por: Li, Xiao, et al.
Publicado: (2022)

Tegaserod mimics the neurostimulatory glycan polysialic acid and promotes nervous system repair
por: Bushman, J., et al.
Publicado: (2013)

Improving Aqueous Solubility and In Vitro Pharmacokinetic Properties of the 3-Nitroimidazo[1,2-a]pyridine Antileishmanial Pharmacophore
por: Paoli-Lombardo, Romain, et al.
Publicado: (2022)

Inhibiting Acetylcholinesterase to Activate Pleiotropic Prodrugs with Therapeutic Interest in Alzheimer’s Disease
por: Toublet, François-Xavier, et al.
Publicado: (2019)

The Effect of Tegaserod on Symptoms and Quality of Life in Korean Women with Irritable Bowel Syndrome with Constipation
por: Kim, Yong Sung, et al.
Publicado: (2010)

Tegaserod Maleate Inhibits Esophageal Squamous Cell Carcinoma Proliferation by Suppressing the Peroxisome Pathway
por: Wu, Xiangyu, et al.
Publicado: (2021)

Effects of tegaserod on bile composition and hepatic secretion in Richardson ground squirrels on an enriched cholesterol diet
por: Mathison, Ronald, et al.
Publicado: (2006)

Tegaserod Maleate Suppresses the Growth of Gastric Cancer In Vivo and In Vitro by Targeting MEK1/2
por: Wang, Zitong, et al.
Publicado: (2022)

Effect of illicit direct to consumer advertising on use of etanercept, mometasone, and tegaserod in Canada: controlled longitudinal study
por: Law, Michael R, et al.
Publicado: (2008)

The Zelnorm epidemiologic study (ZEST): a cohort study evaluating incidence of abdominal and pelvic surgery related to tegaserod treatment
por: Seeger, John D, et al.
Publicado: (2012)

Effect of the 5-HT(4) receptor agonist tegaserod on the expression of GRK2 and GRK6 in the rat gastrointestinal tract
por: Nedi, Teshome, et al.
Publicado: (2018)

Development of Novel Potential Pleiotropic Compounds of Interest in Alzheimer’s Disease Treatment through Rigidification Strategy
por: Lecoutey, Cédric, et al.
Publicado: (2021)

Development and Evaluation of Repurposed Etoricoxib Loaded Nanoemulsion for Improving Anticancer Activities against Lung Cancer Cells
por: Md, Shadab, et al.
Publicado: (2021)

Repurposing of Tibolone in Alzheimer’s Disease
por: Barreto, George E.
Publicado: (2023)

Increased cholinergic contractions of jejunal smooth muscle caused by a high cholesterol diet are prevented by the 5-HT(4 )agonist – tegaserod
por: Mathison, Ronald, et al.
Publicado: (2006)

Tegaserod for Irritable Bowel Syndrome With Constipation in Women Younger Than 65 Years Without Cardiovascular Disease: Pooled Analyses of 4 Controlled Trials
por: Shah, Eric D., et al.
Publicado: (2021)

Quercetin Nanoemulsion Ameliorates Neuronal Dysfunction in Experimental Alzheimer’s Disease Model
por: Alaqeel, Nouf K., et al.
Publicado: (2022)

New 8-Nitroquinolinone Derivative Displaying Submicromolar in Vitro Activities against Both Trypanosoma brucei and cruzi
por: Pedron, Julien, et al.
Publicado: (2020)

In silico repurposing of antipsychotic drugs for Alzheimer’s disease
por: Kumar, Shivani, et al.
Publicado: (2017)

Rational design of novel benzisoxazole derivatives with acetylcholinesterase inhibitory and serotoninergic 5-HT(4) receptors activities for the treatment of Alzheimer’s disease
por: Lalut, Julien, et al.
Publicado: (2020)

Conceptual Framework of the Design of Pleiotropic Drugs against Alzheimer’s Disease
por: Guiselin, Thomas, et al.
Publicado: (2023)

Combining two repurposed drugs as a promising approach for Alzheimer's disease therapy
por: Chumakov, Ilya, et al.
Publicado: (2015)

A New Thienopyrimidinone Chemotype Shows Multistage Activity against Plasmodium falciparum, Including Artemisinin-Resistant Parasites
por: Bosson-Vanga, Henriette, et al.
Publicado: (2021)

Potential repurposing of oncology drugs for the treatment of Alzheimer's disease
por: Araki, Wataru
Publicado: (2013)

Repurposed agents in the Alzheimer’s disease drug development pipeline
por: Bauzon, Justin, et al.
Publicado: (2020)

Repurposing Licensed Drugs for Use Against Alzheimer’s Disease
por: Norins, Leslie C.
Publicado: (2021)

Single-cell-led drug repurposing for Alzheimer’s disease
por: Parolo, Silvia, et al.
Publicado: (2023)

Magnetic Nanoemulsions: Comparison between Nanoemulsions Formed by Ultrasonication and by Spontaneous Emulsification
por: Rodríguez-Burneo, Nathalia, et al.
Publicado: (2017)

Development and Study of Nanoemulsions and Nanoemulsion-Based Hydrogels for the Encapsulation of Lipophilic Compounds
por: Demisli, Sotiria, et al.
Publicado: (2020)

Shape-Controlled Nanoparticles from a Low-Energy Nanoemulsion
por: Rolland, Manon, et al.
Publicado: (2021)

First Synthesis of Racemic Trans Propargylamino-Donepezil, a Pleiotrope Agent Able to Both Inhibit AChE and MAO-B, with Potential Interest against Alzheimer’s Disease
por: Guieu, Benjamin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hh3dm8sug2p8u4u8vmbrbdpurq